Tag: FDA and clinical trials
![carcinoid syndrome lexicon pharmaceuticals telotristat etiprate clinical trial](https://www.carcinoid.org/wp-content/uploads/2015/08/carcinoid-syndrome-lexicon-pharmaceuticals-telotristat-etiprate-clinical-trial-300x300.jpg)
Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial
August 5, 2015
Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…
READ MORE![ebrahim delpassand md](https://www.carcinoid.org/wp-content/uploads/2012/11/ebrahim-delpassand-md.jpg)
First U.S. Center to Enroll Patients in International, Multicenter Clinical Trial of Lu-177 Octreotate
November 20, 2012
Excel Diagnostics and Nuclear Oncology Center in Houston, Texas, is the first center in the United States to start recruiting patients in a multicenter randomized clinical trial of Lu-177 Octreotate in patients with progressive midgut carcinoid. …
READ MORE